CTOs on the Move

Medical Imaging Applications

www.mia-llc.com

 
Medical Imaging Applications is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mia-llc.com
  • 832 Forest Hill Dr
    Coralville, IA USA 52241
  • Phone: 319.358.1529

Executives

Name Title Contact Details

Similar Companies

Geriatric Medical

Geriatric Medical is a Everett, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dr. Newton's Naturals

Dr. Newton's Naturals is a South Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ampersand Health

Ampersand Health is developing markets, opening clinics and implementing proprietary workflows through investment in the most powerful and efficient mechanism for improving health and reducing costs - primary care. Ampersand Health tailors its solutions for health plans operating in inner city markets serving Medicare Advantage, Managed Medicaid and Dual Eligible members.

Aegea Medical

AEGEA Medical was founded in 2008 to develop technology that aspires to utilize water vapor to treat a variety of women`s health conditions. Led by an experienced management team, and supported by a committed investor group, AEGEA Medical has established an expanding Intellectual Property (IP) portfolio.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.